Breast Cancer Market Revenue Growth, Regional Share Analysis & Forecast Till 2027

 


Breast cancer is one of the major type of cancer in women. To ensure the effective treatment of the patient early stages diagnosis of the breast cancer is important. According to WHO, 200,000 new cases are diagnosed worldwide and the number will increased in the coming future. Different types of treatments are available but there is no absolute treatment. Global breast cancer market is driven by increasing prevalence of breast cancer which is due to adoption of unhealthy lifestyle, genetic profile of the patients and continuous exposure to harmful radiations. Increasing government support and awareness also contributed in the growth of the market. But side effect associated with the therapy and high cost of treatment has hamper the growth of the market.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/1379

Segmentation:

Global breast cancer market is segmented on the basis of type into invasive ductal carcinoma, invasive lobular carcinoma and other. On the basis of treatment they are segmented into chemotherapy, surgery & radiation therapy, targeted therapy, biologic therapy, hormone therapy and other. Chemotherapy is further segmented into antimetabolites, anthracyclines, taxanes and alkylating agents. Target therapy is further segmented into tyrosine kinase inhibitors and monoclonal antibodies Hormone therapy is further segmented into selective estrogen-receptor modulators (SERMs), aromatase inhibitors and others. On the basis of end users the market is segmented into hospital pharmacies, private pharmacies and other.

Competitive Analysis

The major key player for the global breast cancer market are Pfizer (US), Novartis AG (Switzerland), Oncogenex (US), Apthera Inc (UK), BioNumerik Pharmaceuticals (US), Oncothyreon Inc (US), Astellas (Japan), Bipar Sciences (US), Puma Biotechnology (US), Sanofi S.A. (US), Eli Lilly and Company (US), AstraZeneca (UK), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline (UK), Genentech (US), Teva Pharmaceutical Industries (Israel), Sun Pharmaceutical Industries Ltd (India), Accord Healthcare, Inc. (India), Gilead Sciences, Inc. (US), Bristol-Myers Squibb company (US), Actavis, Inc. (US), Hospira, Inc. (US), Bayer AG (Germany)

Unavailability of absolute treatment has given a wide range of platform for the development of the market. Companies are focusing on the development of new products which will be cost effective and will have minimum side effects. Some major players has adopted strategies of acquisitions and strategic alliances for the growth of the market. Moreover, competition amongst new market players is also expected to upsurge growth for breast cancer drugs market over the next seven years.

Pfizer is among the world's largest pharmaceutical companies headquartered in US. In March 2017, company has got FDA approval of IBRANCE for the first line HR+, HER2- metastatic breast cancer. It is the only cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor approved by the FDA as a first line therapy. In 2016, Pfizer has acquired Medivation to increase its oncology market.

AstraZeneca is an Anglo–Swedish multinational pharmaceutical company headquarters in UK. In 2017, company has got approval for three new drugs. Lynparza is one of three new drugs which is PARP inhibitors. This drug has shown a most promising results in Phase III clinical trials and may generate $1.2 billion by 2020.

Novartis AG is one of the largest Swiss pharmaceutical company. In 2017, company has got FDA approval for Kisqali as first-line treatment for HR+/HER2- metastatic breast cancer with the combination of any aromatase inhibitor. Company has announced collaboration with IBM Watson Health to explore development of new techniques. In 2016, LEE011 is approved by FDA as first-line treatment for breast cancer.

GlaxoSmithKline is the world sixth largest pharmaceutical company headquartered in UK. Tykerb is the most widely used drug of the company. In 2015, GSK has announced its acquisition on GlycoVaxyn which is a Swiss pharmaceutical company.

F. Hoffmann-La Roche AG is among the five largest pharmaceutical company in the world headquartered in Switzerland. In 2014, Roche has got an FDA approval of Kadcyla (trastuzumab emtansine) which is the first antibody-drug conjugate for treating HER2-positive metastatic breast cancer.

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/global-breast-cancer-market-1379

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Have a Look at Related Reports:

Medical Waste Management Equipment Market - https://www.globenewswire.com/en/news-release/2019/07/25/1887936/0/en/Medical-Waste-Management-Equipment-Market-to-Exhibit-a-Healthy-Growth-Over-2022-High-Adoption-Rate-Makes-North-America-the-Largest-Market-for-Medical-Waste-Management.html

Appendicitis Market - https://www.globenewswire.com/en/news-release/2019/07/26/1892218/0/en/Appendicitis-Market-Expanding-at-a-CAGR-of-4-06-to-Reach-USD-13-026-40-Million-by-2024-Market-Research-Future.html

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com


Location: New York, NY, USA

Comments

Post a Comment

Popular posts from this blog

Digital Pathology Market Research, Size, Revenue, Trends, Competitive Landscape Study & Analysis, Forecast To 2028

Image
  The growing number of innovations in the areas of pathology would further increase the size of the market to a great deal, in the next six years. According to MRFR, the Digital Pathology Market is expected to register a CAGR of 6.5% over the review period from 2021 to 2028 and expected to reach USD 1.4 Billion by 2028. Digital Pathology or Computational Pathology leverages completely new perceptions through data analysis, enabling pathologists to consult on treatment options. The rapidly evolving pathology sector is a key element of modern diagnostic practices. There have been several innovations and widespread adoption of digital pathology. It has long been realized that the traditional histopathology is inefficient as it exposes samples to various handlers, increasing the scope for human error. The digital pathology, on the other hand, eliminates the risk factors, while also providing the pathologist with the necessary images and clinical information to generate the most a...
Read more

Structural Heart Devices Market Size, Key Player Revenue, SWOT, PEST & Porter’s Analysis Till 2027

Image
Structural heart diseases   are problems associated with the valves or tissues of the heart. These diseases may be congenital or might be acquired later in life. Structural heart diseases include cardiomyopathy, myocarditis, aortic valve stenosis, heart valve disease, atrial septal defect, mitral valve regurgitation, and others. As per the latest report of Market Research Future (MRFR), the structural heart devices market is poised to expand at CAGR of 10.4% over the forecast period. The  structural heart devices market  is primarily driven by a radical rise in the incidence rate of non-coronary heart disorders, increased demand for minimally invasive surgical procedures, and improving reimbursement schemes. In the past few years, tremendous advances have been achieved with respect to the understanding of these diseases, and accordingly, therapeutic modalities have been developed. A number of clinical trials and technology developments are underway, which is likely to pro...
Read more

Anal Fissure Treatment Market Competitive Landscape, Growth Factors, Revenue Analysis Till 2030

Image
  The global  anal fissure treatment market  is expected to rise and touch a valuation of USD 2,526.5 million by 2023, at a 7.6% CAGR during the forecast period. Anal fissures are small tears near the mucosal lining of the anus. Deeper cuts may take a combination of oral and topical medicine to alleviate the pain. The anal fissure treatment market is expected to thrive owing to the booming pediatric and geriatric patient pool. Advances in technology coupled with various treatment options is likely to lead to a windfall for the market over the forecast period. High incidence of constipation is predicted to drive the need for anal fissure treatments. This is backed by vulnerability of the elderly which find it difficult to pass stools properly. According to the American Gastroenterological, nearly 33% of Americans above 60 experience the condition. Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/3841 Unhealthy lifestyles adopted by pat...
Read more